Gadoquatrane clinical trials
Also written BAY1747846.
How each study uses gadoquatrane is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 12 Jun 2026 · AMBELVIST · NDA 219627 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 3 |
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses gadoquatrane is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related ProblemsCompletedPhase 3BayerNCT05915702Written as Gadoquatrane (BAY1747846)
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)CompletedPhase 3BayerNCT05915728Written as Gadoquatrane (BAY1747846)
- A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)CompletedPhase 3BayerNCT05915026Written as Gadoquatrane (BAY1747846)
- A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male ParticipantsCompletedPhase 1BayerNCT06135181Written as Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg
- Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord ConditionsCompletedPhase 2BayerNCT04307186Written as Gadoquatrane (BAY1747846)
- A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male ParticipantsCompletedPhase 1BayerNCT06125366Written as BAY1747846
- A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal FunctionCompletedPhase 1BayerNCT05061979Written as BAY1747846
Codes
What other systems call gadoquatrane · ClinicalTrials.gg INT017515
- UNII (FDA) OZG7J613HKGADOQUATRANEOne source FDA
- NCI Thesaurus C184920GadoquatraneOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OZG7J613HK | GADOQUATRANE | One source FDA |
| NCI Thesaurus | C184920 | Gadoquatrane | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.